Ms. ShuiShui Long
· Teaching Assistant ProfessorVerifiedUniversity of North Carolina at Chapel Hill · Asian Studies
Active 1991–2026
About
Ms. ShuiShui Long is a Teaching Assistant Professor in the Department of Asian and Middle Eastern Studies at the University of North Carolina at Chapel Hill. She received her M.A. in Teaching Chinese as a Foreign Language from the Hong Kong Polytechnic University. Prior to her current position, she taught Chinese language courses at all levels at the University of Virginia from 2015 to 2017 and at Pennsylvania State University from 2017 to 2025. She has also taught in intensive and immersion programs, including UVA in Shanghai, CIEE in Shanghai, Princeton in Beijing (PIB), and Middlebury Language Schools. Since 2021, she has served as a Lead Instructor at Middlebury Chinese School, where she leads Chinese instruction and supports teachers’ professional development. Her research interests focus on curriculum innovation and design, technology-enhanced language learning, task-based instruction, differentiated instruction, teacher training and professional development, and intercultural language education.
Research topics
- Medicine
- Biology
- Internal medicine
- Pathology
- Gastroenterology
- Cell biology
- Intensive care medicine
- Endocrinology
- Immunology
- Cancer research
- Obstetrics
- Genetics
- Molecular biology
Selected publications
Gastrointestinal Endoscopy · 2026-05-01
articleGastroenterology · 2026-05-01
articleGastrointestinal Endoscopy · 2026-05-01
articleGastroenterology · 2026-05-01
articleGastrointestinal Endoscopy · 2026-05-01
articleGastroenterology · 2026-05-01
article56 Treatment Utilization in Women of Childbearing Age vs Men in IBD: A US Claims Database Study
The American Journal of Gastroenterology · 2025-12-01
articleSenior authorThe American Journal of Gastroenterology · 2025-10-01
article1st authorCorrespondingIntroduction: We assessed whether real world patients with Crohn’s disease (CD) or ulcerative colitis (UC) are meeting STRIDE II treatment targets. These results are from an ongoing study. Methods: This substudy prospectively enrolls adults with CD or UC from 15 community or academic sites in the longitudinal US-based consortium, TARGET-IBD. Gastroenterologists consent patients to complete patient reported outcomes (PROs) at 6 months (±4 weeks) after initiating advanced therapy (AT). We excluded UC patients with prior total colectomy. Analytic outcomes were: inflammatory bowel disease disability index (IBD-DI, score of ≥15 indicates mild or worse disability), FACIT-Fatigue (score of <30 indicates severe fatigue), PRO-2 CD, PRO-2 UC and NRS Urgency. PRO-2 CD active disease is stool frequency >2.8 stools/day or abdominal pain >1.0 (range 0-3). PRO-2 UC active disease is stool frequency of more than 1-2 stools per day more than normal or any rectal bleeding. Active bowel urgency is a score ≥2. Patient characteristics and PROs were analyzed descriptively. Results: Of 196 patients currently enrolled, 58 (32 CD and 26 UC) had completed 6-month PROs at the datacut, with mean (SD) age of 38.9 years (15.0), 50% women, and 40 (69%) Non-Hispanic White. In the following, denominators represent respondent counts for each PRO. Most patients (41 of 55, 75%) reported mild or worse disability (76% CD and 73% UC). Twenty-six patients (46%) reported severe fatigue (53% CD and 38% UC). The mean PRO-2 CD score was 6.7 (5.7). CD patients had a mean of 1.7 (2.0) soft stools/day and mean abdominal pain score of 0.7 (0.7). Six CD patients (19%) reported >2.8 soft stools/day; Seven CD patients (23%) reported abdominal pain score >1. The mean PRO-2 UC score was 1.3 (1.3), 5 patients (20%) reported ≥3 “stools/day more than normal”, and 6 (24%) patients reported rectal bleeding. Sixteen (64%) UC patients were in remission. Of 49 patients responding to the NRS Urgency measure, 33 (67%) reported bowel urgency (≥2). Among 31 CD patients, 25 (81%) reported bowel urgency, mean score 3.5 (2.6). Eight of 18 UC patients (44%) reported bowel urgency, mean 2.8 (3.0). Conclusion: In this analysis of 58 patients with moderate to severe CD or UC, many still had suboptimal quality of life 6 months after starting AT. Numerous patients missed STRIDE-II treatment goals, especially in disability and fatigue. These findings show key unmet needs in IBD care.
UNC Libraries · 2025-10-17
articleOpen accessChildren with inflammatory bowel disease (IBD) may have diminished serologic response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and increased risk for subsequent severe coronavirus disease 2019 (COVID-19) infection. We sought to describe outcomes among those who developed SARS-CoV-2 infection following vaccination, characterize SARS-CoV-2 antibodies 1 year post-vaccination, and identify factors associated with durable serologic response.We recruited children with IBD who received ≥2 doses of SARS-CoV-2 vaccine and prospectively collected data on (1) demographics, IBD characteristics, and therapy and (2) SARS-CoV-2 vaccination, testing, and infection symptoms. Serum was obtained for measurement of anti-receptor-binding domain IgG antibodies following a 2-part immunization at 12 and 52 weeks.We enrolled 298 participants (mean age 11.9 ± 3.82, 50% female, 67% Crohn’s disease). Symptomatic COVID-19 infection after vaccination occurred in half of the participants, although only 2 (1%) required hospitalization. Anti-tumor necrosis factor alpha (TNF-α) was associated with higher likelihood of symptomatic COVID-19 infection, with an adjusted hazard ratio of 2.7 (95% CI, 1.5-5.0; P = .001). Nearly all participants (99%) had detectable antibody at Week 52. Children aged 1-5 years had lower 52-week antibody level compared to older children (P = .04), as did those on anti-TNF-α therapy (P = .007) and those who received only 2 vaccine doses prior to Week 52 (P < .001). SARS-CoV-2 vaccination provides lasting serologic response and protection against severe COVID-19 for most children with IBD, despite the use of lower vaccine doses in younger children and wide-ranging classes of immunosuppressive therapies.We demonstrate high rates of durable antibody response and low rates of coronavirus disease 2019-related hospitalization 1 year following severe acute respiratory syndrome coronavirus 2 vaccination in children with inflammatory bowel disease. Anti-tumor necrosis factor alpha therapy, young age, and fewer vaccine doses were associated with lower 52-week antibody level.
UNC Libraries · 2025-08-16
articleOpen access
Frequent coauthors
- 218 shared
Michael D. Kappelman
- 166 shared
Robert S. Sandler
- 112 shared
Hans Herfarth
University of North Carolina at Chapel Hill
- 110 shared
Edward L. Barnes
University of North Carolina at Chapel Hill
- 108 shared
Riley Craig
University of North Carolina at Chapel Hill
- 102 shared
Xian Zhang
National Centre for Clinical Research on Emerging Drugs
- 81 shared
Christopher F. Martin
University of North Carolina at Chapel Hill
- 75 shared
Wenli Chen
Gansu Agricultural University
Awards & honors
- First Janssen Language Teaching Award in Asian Studies, The…
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Ms. ShuiShui Long
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup